# Incretin-based Therapy in Late Preclinical Type 1 Diabetes

> **NCT02898506** · PHASE2 · COMPLETED · sponsor: **University of Oulu** · enrollment: 13 (actual)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **DRUG:** Victoza®
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02898506
- **Lead sponsor:** University of Oulu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2021-06
- **Final completion:** 2021-06
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2022-01-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02898506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02898506, "Incretin-based Therapy in Late Preclinical Type 1 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02898506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*